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Abstract
Background: There are considerable geographical differences
in the occurrence of extended-spectrum beta-lactamase
(ESBL)-producing bacteria, both in the community and in the
hospital setting. Our aim was to assess risk factors for
bloodstream, urinary tract, and vascular catheter-associated
infections with ESBL-producing Escherichia coli and Klebsiella
pneumoniae at a tertiary care hospital in a low-prevalence
country.
Methods: We performed a case–control study comparing 58
patients with infections due to ESBL-producing E. coli or
K. pneumoniae vs 116 controls with infections due to non-
ESBL producing organisms at the University Hospital Zurich,
Switzerland, between 1 July 2005 and 30 June 2007.
Results: Cases included 15 outpatients and 43 inpatients.
Multivariable analyses found three risk factors for ESBL-
producing isolates: begin of symptoms or recent antibiotic
pre-treatment in a foreign country (odds ratio [OR] 27.01,
95% confidence interval [CI] 2.38–1,733.28], p = 0.042),
antibiotic therapy within the year preceding the isolation of
the ESBL-producing strain (OR 2.88, 95% CI 1.13–8.49,
p = 0.025), and mechanical ventilation (OR 10.56, 95% CI
1.06–579.10, p = 0.042).
Conclusions: The major risk factors for infections due to
ESBL-producing bacteria were travel in high-prevalence
countries, prior antibiotic use, and mechanical ventilation
during a stay in the intensive care unit. Community-ac-
quired infections were documented in 17% of the patients.
An early identification of risk factors is crucial to providing
the patients an optimal empiric antibiotic therapy and to
keep the use of carbapenems to a minimum.
Infection 2010; 38: 33–40
DOI 10.1007/s15010-009-9207-z
Introduction
Extended-spectrum beta-lactamases (ESBL) are beta-
lactamases that confer bacterial resistance to all penicil-
lins, first-, second- and third-generation cephalosporins,
and aztreonam through their enzymatic hydrolysis of the
four-atom ring (beta-lactam) of these antibiotics. They
are most often found in strains of Escherichia coli and
Klebsiella pneumoniae [1, 2]. While ESBLs can be inhib-
ited by beta-lactamase inhibitors, such as clavulanic acid,
treating infections due to ESBL-producing Gram-nega-
tive bacteria is challenging due to the limited availability
of antibiotics that are not susceptible to hydrolysis by
ESBLs. In addition, the use of beta-lactams in combina-
tion with beta-lactamase inhibitor agents for the treat-
ment of serious infections with ESBL-producing bacteria
is still a matter of debate [3]. Therefore, some experts
recommend the use of a carbapenem antibiotic for all
cases of serious infection with ESBL-producing bacteria
[4].
Infections with ESBL-producing Enterobacteriaceae
originally emerged primarily in the hospital setting. Pa-
tients at high risk for developing colonization or infection
with ESBL-producing organisms are often seriously ill,
have (had) a prolonged hospital stay, or are in need of
invasive medical devices [1, 2, 5–9]. Several studies have
found a relationship between third-generation cep-
halosporin use and colonization or infections with an
ESBL-producing strain [10]. Since 2001 [11], reports of
community-acquired infections of ESBL have emerged,
which makes the epidemiology of ESBL-producing bacteria
yet more complex [12]. E. coli is the most common cause of
community-acquired urinary tract infections, and ESBL-
producing isolates of E. coli are frequently resistant to many
of the antimicrobial agents recommended for the treatment
of such infections. The presence of community-acquired
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ESBL-producers plus the potential for plasmid-mediated
resistance to quinolone and carbapenem antibiotics will
undoubtably create significant therapeutic problems in the
future [13, 14].
There are considerable geographical differences in
the occurrence of ESBLs, both in the community and in
the hospital setting. Even though Switzerland is a country
with a relatively low prevalence rate, community-acquired
ESBLs have already emerged [15]. Given this new ESBL-
epidemiology, there is a need to re-evaluate established
risk factors.
The objective of this study was to assess risk factors
for bloodstream, urinary tract, and catheter-associated
infections with ESBL-producing E. coli and K. pneumo-
niae in a low-prevalence country.
Patients and Methods
Setting
We performed a case–control study at the University Hospital
Zurich, an 800-bed tertiary care teaching hospital that covers all
specialties except for pediatrics and orthopedics. Six intensive
care units (ICUs) provide a full range of clinical services in dif-
ferent departments of surgery and internal medicine.
The computerized database of the Institute of Medical
Microbiology, University of Zurich, which compiles and pro-
cesses all microbiological samples of the University Hospital
Zurich, was used to identify patients with E. coli or K. pneumoniae
detected in blood cultures, cultures from vascular catheters, and
cultures from urine in the time period from 1 July 2005 through to
30 June 2007. As most infections due to ESBL-producing E. coli
and K. pneumoniae occurred and were treated in the departments
of Internal Medicine, Surgery, Gynecology and Obstetrics, and
Urology, only patients treated in these departments were included
in this analysis. Other clinical samples as well as surveillance
swabs yielding ESBL-producing E. coli and K. pneumoniae and
infections due to other ESBL-producing Enterobacteriaceae were
not included in this analysis.
Case and Control Patients
Case patients were defined as patients presenting with blood-
stream infections (systemic inflammatory response syndrome
and blood cultures positive for an ESBL-producing strain of
E. coli or K. pneumoniae [16]), those with local or systemic
signs of infection from an intravascular catheter with a positive
catheter tip culture (> 5 cfu/ml [17]) with an ESBL-producing
E. coli or K. pneumoniae, and those with asymptomatic
bacteriuria or symptomatic urinary tract infection (e.g., fever,
dysuria, urgency, frequency, suprapubic tenderness, or flank
pain) with documentation of an ESBL-producing E. coli or
Klebsiella pneumoniae (‡ 104 cfu/ml) in the urine. Symptom-
atic case patients with pyelonephritis, indwelling urinary
catheters, or urinary tract obstruction were assigned to have a
complicated urinary tract infection. Asymptomatic patients
with positive urine cultures, including those with indwelling
bladder catheters, were considered to have asymptomatic
bacteriuria.
Control patients were defined as patients presenting with
the same types of infections as those of the case patients, but with
infections due to non-ESBL-producing E. coli or K. pneumoniae.
Two controls were matched with every case patient. The
matching priorities in decreasing order were: bacterial isolate,
specimen, department, age (± 5 years), and gender.
Data Collection and Definitions
Clinical and demographic data of cases and controls were col-
lected from patients’ charts. The variables evaluated as possible
risk factors were: nosocomial onset of infection, ICU stay,
mechanical ventilation, central venous catheter, urinary catheter
or pigtail catheter in the urinary tract at the time of infection,
hospitalization within the preceding 365 or 30 days, urological or
general surgery within the preceding 365 or 30 days, prior anti-
biotic use within the year preceding the infection, documented
urinary tract anomaly, recurrent urinary tract infections accord-
ing to anamnestic information, renal insufficiency, prior renal
transplantation, hemodialysis, malignoma, diabetes, HIV infec-
tion, neutropenia (< 500 neutrophils/ll), immunosuppressive
medication (corticosteroids and other immunsuppressants), and
travel history. We used the ‘‘Chronic Disease Score’’ to assess
the comorbidity of hospitalized patients [18, 19].
The administration of antibiotics within 1 year prior to the
diagnosis of infection was assessed. One antibiotic course was
defined as the administration of at least one dose of any anti-
bacterial agent. A time interval of > 24 h between the adminis-
tration of two doses was defined to separate one course from
another, unless certain conditions (e.g., renal insufficiency) jus-
tified a dose interval of < 24 h.
Infections were considered to be nosocomial if the patient
was hospitalized in an acute care center for > 24 h prior to
sample collection. Surgical site infections were rated as nosoco-
mial if the infection was related to a surgical procedure per-
formed in the preceding year [20]. Non-nosocomial infections
were either community-acquired or health care-associated. They
were rated as health care associated if they fulfilled any of the
following criteria (adapted from [21]): (1) Patient received iv
therapy at home; received wound care or specialized nursing care
through a health care agency, family, or friends; had self-
administered iv medical therapy in the 30 days before the
infection (patients whose only home therapy was oxygen use
were excluded); (2) patient attended a hospital or hemodialysis
clinic or received iv antineoplastic chemotherapy in the 30 days
before the infection; (3) patient was hospitalized in an acute care
hospital for ‡ 2 days in the 90 days before the infection; (4)
patient resided in a nursing home or long-term care facility.
Microbiological Analysis
Antimicrobial susceptibility testing and screening for ESBL was
performed according to Clinical and Laboratory Standards
Institute recommendations [22]. In brief, the initial screen test to
indicate ESBL production was a ceftazidime inhibition zone
with a diameter £ 22 mm or a cefotaxime inhibition zone
£ 27 mm. Any synergy between amoxicillin/clavulanic acid and
ceftazidime or cefepime (double disk method) or between
piperacillin/tazobactam and cefotaxime in the disk diffusion test
was also taken to be an indication for the organism to be tested
by a phenotypic confirmatory test. A greater than twofold con-
centration decrease in an MIC for ceftazidime or cefepime or for
cefotaxime tested in combination with clavulanic acid versus its
MIC when tested alone was confirmatory for ESBL. In accor-
dance with the CLSI guidelines, all ESBL-producing E. coli
strains were classified as resistant to all penicillins, cephalospo-
rins, aztreonam irregardless of the MICs determined for these
drugs [22].
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Statistical Analysis
All statistical analyses were performed using Intercooled Stata
Software Version 10 for Windows (Stata Corp, College Station,
TX). Categorical data were analyzed using the two-tailed v2 test
or Fisher’s exact test, and continuous data were analyzed by the
Wilcoxon rank-sum test. We used conditional logistic regression
analysis for the univariable and multivariable calculation of risk
factors and odds ratios (OR) with 95% confidence intervals (CI).
A two-tailed test of significance with a p-value < 0.05 was con-
sidered to be statistically significant.
Ethical Approval
The study protocol was approved by the local ethics committee.
Results
Patient characteristics
A total of 174 patients (58 cases and 116 controls) were
included in the analysis (Table 1). 73 (42.0%) patients
were male, of whom 25 (43.1% of case patients) were in
the ESBL group and 48 (41.4% of control patients) in the
non-ESBL group. The mean age (± standard deviation
[SD]) was 52.6 years (± 19.17 years) for cases and
53.51 years (± 18.48 years) for controls. 25.9% of all pa-
tients in each group were treated as outpatients, while 48
patients (27.6%) were treated in the Department of Sur-
gery, 60 (34.5%) in the Department of Internal Medicine,
45 (25.9%) in the Department of Urology, and 21 (12.1%)
in the Department of Gynecology and Obstetrics. E. coli
could be cultured in 153 (87.9%) patients, and K. pneu-
moniae in 21 (12.1%). The mean duration of hospital stay
was 35.4 days (± 39.2 days) for cases and 24.4 days
(± 23.4 days) for controls.
48 (82.8%) patients with infections due to ESBL-
producing E. coli or K. pneumoniae suffered from urinary
tract infections, five (8.6%) suffered from bloodstream
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Table 1
Patient characteristics of cases and controls.
Patient characteristics ESBL group n (%) Non-ESBL group n (%) p-value
Number of patients 58 (100) 116 (100)
Male 25 (43.1) 48 (41.4) 0.871
Age, years (mean ± SD) 52.6 ± 19.2 54.0 ± 18.2 0.637
Outpatients 15 (25.9) 30 (25.9) 1.000
Inpatients 43 (74.1) 86 (74.1) 1.000
Duration of hospital stay, days (mean ± SD) 35.4 ± 39.2 24.4 ± 23.4 0.177
Intensive care stay, days 21 (36.2) 38 (32.8) 0.734
Duration of intensive care stay, days (mean ± SD) 14.2 ± 15.8 9.9 ± 9.4 0.573
Duration of hospital stay before first isolate, days (mean ± SD) 12.2 ± 18.5 8.5 ± 10.0 0.466
Chronic Disease Score (mean ± SD) 6.0 ± 2.6 5.3 ± 2.3 0.136
Nosocomial onset of infection 26 (44.8) 53 (45.7) 1.000
Non-nosocomial onset of infection 32 (55.2) 63 (54.3) 1.000
Health care-associated 22 (37.9) 30 (25.9) 0.080
Community-acquired 10 (17.2) 33 (28.4) 0.080
Comorbidity
Urinary tract anomaly 18 (31.0) 31 (26.7) 0.594
Malignoma 14 (24.1) 24 (20.7) 0.698
Renal insufficiency 6 (10.3) 17 (14.7) 0.486
Hemodialysis 4 (6.9) 3 (2.6) 0.224
Diabetes 8 (13.8) 12 (10.3) 0.615
Sites of infection
Urinary tract infections 48 (82.8) 96 (82.8) 1.000
Asymptomatic bacteriuria 22 (37.9) 46 (39.7) 0.870
Acute uncomplicated urinary tract infection 10 (17.2) 7 (6.0) 0.028
Acute uncomplicated pyelonephritis 0 (0) 10 (8.6) 0.032
Complicated urinary tract infection 16 (27.6) 28 (24.1) 0.712
Other or unclear diagnosis 0 (0) 5 (4.3) 0.176
Bacteremia 5 (8.6) 15 (12.9) 0.461
Peritonitis 2 (3.4) 4 (3.4) 1.000
Urosepsis 2 (3.4) 4 (3.4) 1.000
Burns 1 (1.7) 2 (1.7) 1.000
Septic abortion 0 (0) 1 (0.9) 1.000
Perinephritic abscess 0 (0) 1 (0.9) 1.000
Unknown focus 0 (0) 3 (2.6) 0.552
Vascular catheter-associated infection 5 (8.6) 5 (4.3) 0.304
ESBL: Extended-spectrum beta-lactamase; SD: standard deviation
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infections, and five (8.6%) had vascular catheter-associ-
ated infections. In the ESBL group, 26 (44.8%) patients
had a nosocomial infection: Ten (17.2%) had acquired
their infection in the community, whereas in 22 (37.9%)
patients, the infection was rated as health care-associated.
The ten patients with non-health care-associated
infections were assessed individually (Table 2). Six of
these patients had been pre-treated with antibiotics during
the preceding year, two of whom had been hospitalized
during this same period. Two of the remaining patients
had a history of urological disease (recurrent urinary tract
infections or benign prostatic hyperplasia), one was
pregnant at the time of the first positive culture, and one
patient had no history of any disease.
96 (82.8%) control patients had an infection with E.
coli or K. pneumoniae related to the urinary tract, 15
(12.9%) had a bacteremia, and five (4.3%) had a vascular
catheter-associated infection. 53 (45.7%) infections in
control patients were rated as nosocomial, 30 (25.9%)
were rated as health care-associated, and 33 (28.4%) were
rated as community-acquired.
Co-morbidities and characteristics according to the
duration of hospitalization and ICU stay were equally
distributed among the two groups. Patients from the
ESBL group had significantly more acute uncomplicated
urinary tract infections than control patients (17.2% vs
6.0%, p = 0.028). A tendency in case patients to have
more health care-associated infections than control pa-
tients was observed; however, the trend did not reach
statistical significance (37.9% vs 25.9%, p = 0.080).
Risk Factors for Infections due to ESBL-producing
Organisms
The risk factors for bacteremia, urinary, or vascular
catheter-associated infections with ESBL-producing E.
coli or K. pneumoniae derived from the univariable and
multivariable analysis are shown in table 3. The univari-
able analysis revealed that the begin of symptoms or re-
cent treatment in a foreign country was strongly
associated with infections with ESBL-producing strains
(OR 16.96, 95% CI 2.49–788.96, p < 0.001). Another risk
factor was antibiotic therapy within the year preceding the
isolation of the ESBL-producing strain (OR 3.03, 95% CI
1.33–7.68, p = 0.006). Mechanical ventilation (OR 6.27,
95% CI 1.30–63.48, p = 0.017) increased the risk of
infections due to ESBL-producing E. coli or K. pneumo-
niae, especially if the duration of ventilation exceeded
14 days. Stay in the ICU itself was not associated with a
significantly increased risk. However, an increasing risk
was found with increasing length of ICU stay. These three
risk factors were identified in both the univariable and
multivariable model.
Prior hospitalization in Switzerland or any kind of
surgery did not enhance the risk for infections due to
ESBL-producing E. coli or K. pneumoniae. Other factors
not associated with an increased risk for such an infection
were nosocomial onset of infection, urinary tract anoma-
lies, urinary tract devices, such as urinary catheters or
pigtail catheters, central venous catheters, and/or co-
morbidities, such as renal insufficiency, hemodialysis,
malignomas, diabetes, HIV infection, neutropenia and/or
immunosuppressive medication.
Prior Antibiotic Use
The upper part of table 4 depicts the antibiotic treatment
history of the cases and controls within 1 year preceding
the first isolate in terms of the number of antibiotic
courses received. Only 15 (25.9%) case patients were not
pretreated with antibiotics in the observation period,
whereas 54 (46.6%) control patients had an uneventful
treatment history. Patients who received none or only one
course of antibiotics within the preceding year were sig-
nificantly less often infected with an ESBL-producing
strain (43.1% [cases] vs 71.6% [controls], p < 0.001).
Pretreatment with three or more courses of any antibiotic
resulted in a marked increase of the risk for infection with
an ESBL-producing strain (41.4% [cases] vs 19.8% [con-
trols], p = 0.004).
The lower part of table 4 shows the distribution of
antibiotics used for pre-treatment. A significant increase in
the number of infections due to ESBL-producing bacteria
was found in patients with a history of previous treatment
with cephalosporins (27.6% vs 9.5%, p = 0.003), carba-
penems (13.8% vs 4.3%, p = 0.033), quinolones (55.2% vs
21.6%, p < 0.001), or aminoglycosides (8.6% vs 0.9%,
p = 0.016).
Discussion
Our case–control study of 58 patients with ESBL and 116
controls with non-ESBL-producing E. coli and K. pneu-
monia infections, performed at a tertiary care university
hospital in a low-prevalence country, identified three
major risk factors: Mechanical ventilation, prior antibiotic
use, and onset of symptoms and/or start of treatment
abroad. Two factors in particular were found to increase
the risk for infections with these multi-resistant organisms:
Prior exposure to cephalosporins, carbapenems, quino-
lones, and aminoglycosides and exposure to three or more
courses of antibiotic therapy within the preceding year.
Only two case patients with community-acquired infec-
tions were not pre-treated with any antibiotics within the
preceding year and did not have any underlying urinary
tract disorder.
Exposure to antibiotics reduces the drug-susceptible
normal flora and enhances the vulnerability of the patient
to colonization by resistant organisms. In addition,
organisms that are resistant to several drugs are more
likely to be selected by the use of one of these antibiotics.
Prior antibiotic use, especially of beta-lactams, is a well-
recognized risk factor for infection with ESBL-producing
organisms [1, 2, 6, 7]. The results of our study confirm the
increase of risk of infection after prior exposure to ceph-
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alosporins and quinolones. We also found that carba-
penems and aminoglycosides were statistically associated
with an increased risk, but the relevance of these findings
remains unclear because of the low number of patients
who were treated with these antibiotics. Different study
designs and definitions as well as new mechanisms of
resistance to fluoroquinolones and aminoglycosides may
be reasons why other trials were unable to demonstrate an
association with the previous use of these antibiotics
[23–25]. The finding that quinolones are a risk factor is
particularly worrisome as the use of these antibiotics in
the community has been increasing over time [26].
Switzerland is currently regarded a country with a
low prevalence of ESBL-producing bacteria [27], with an
estimated prevalence rate of 0.7% [15]. The fact that the
start of symptoms and/or therapy abroad is strongly
associated with ESBL production may reflect the higher
prevalence of such bacteria in other countries. Prophy-
lactic infection control measures are routinely performed
in our hospital in patients who are relocated from hos-
pitals abroad. The impact of community-acquired infec-
tions due to ESBL-producing bacteria may warrant a
change in infection control measures for tourists in the
future.
Cordery et al. [5] evaluated risk factors for the
acquisition of ESBL-producing organisms in ICUs and
were unable to identify any individual risk factor. How-
ever, we were able to demonstrate that mechanical ven-
tilation itself and the length of mechanical ventilation
were both strongly associated with an increased risk for
infection with ESBL-producing E. coli and K. pneumo-
niae. A stay in the ICU itself was not associated with an
increased risk.
The limitations of our study include the inherent
weaknesses of case–control studies. As such, the selection
of matching criteria may mask certain risk factors. In our
study, for example, the selection of age as a matching
criterion may have concealed the increasing risk of
infections from ESBL-producing bacteria with increasing
age [1]. Furthermore, with increasing matching of the
criteria selected, there is a decrease in the number of risk
factors that can be detected because the patients become
more similar. However, a strict matching strategy results
in similar medical histories of cases and controls and
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Table 3
Univariable and multivariable conditional logistic regression analysis of risk factors for infections with extended-spectrum beta-
lactamase-producing E. coli and K. pneumoniae.
Variable ESBL
group,
n (%)
Non-ESBL
group,
n (%)
Univariable analysis Multivariable analysis
p-value OR (95% CI) p-value OR (95% CI)
Nosocomial onset of infection 26 (44.8) 53 (45.7) 1.000 0.93 (0.34–2.64)
ICU stay 21 (36.2) 38 (32.8) 0.606 1.64 (0.42–7.05)
Duration of ICU stay between 1 and 6 days 8 (13.8) 16 (13.8) 0.869 1.36 (0.31–6.19)
Duration of ICU stay between 7 and 13 days 5 (8.6) 15 (12.9) 0.657 2.24 (0.26–22.82)
Duration of ICU stay 14 or more days 8 (13.8) 7 (6.0) 0.151 6.88 (0.61–111.12)
Central venous catheter 18 (31.0) 34 (29.3) 0.681 1.40 (0.47–4.55)
Mechanical ventilation 15 (25.9) 17 (14.7) 0.017 6.27 (1.30–63.48) 0.042 10.56 (1.06–579.10)
Duration of ventilation between 1 and 6 days 4 (6.9) 4 (3.4) 0.202 3.97 (0.57–45.68)
Duration of ventilation between 7 and 13 days 3 (5.2) 9 (7.8) 0.761 2.68 (0.13–56.37)
Duration of ventilation 14 or more days 8 (13.8) 4 (3.4) 0.008 16.95 (1.74–956.72)
Pigtail catheters in urinary tract 5 (8.6) 13 (11.2) 0.787 0.73 (0.18–2.55)
Urinary catheter 30 (51.7) 52 (44.8) 0.400 1.48 (0.65–3.41)
Hospitalization within last 30 days 18 (31.0) 34 (29.3) 0.944 1.09 (0.50–2.35)
Hospitalization within last year 32 (55.2) 64 (55.2) 0.952 1.08 (0.53–2.19)
Surgery within last 30 days 12 (20.7) 22 (19.0) 0.938 1.12 (0.45–2.73)
Surgery within last year 19 (32.8) 39 (33.6) 1.000 0.96 (0.45–1.99)
Prior antibiotic use within last year 43 (74.1) 62 (53.4) 0.006 3.03 (1.33–7.68) 0.025 2.88 (1.13–8.49)
Urinary tract anomaly 18 (31.0) 31 (26.7) 0.628 1.33 (0.54–3.39)
Recurrent urinary tract infections 16 (27.6) 21 (18.1) 0.125 2.25 (0.82–6.61)
Renal insufficiency 6 (10.3) 17 (14.7) 0.601 0.69 (0.21–1.91)
Renal transplantation 1 (1.7) 11 (9.5) 0.093 0.17 (0.00–1.20)
Hemodialysis 4 (6.9) 3 (2.6) 0.263 5.09 (0.46–275.59)
Malignoma 14 (24.1) 24 (20.7) 0.691 1.33 (0.48–3.57)
Diabetes mellitus 8 (13.8) 12 (10.3) 0.664 1.39 (0.46–3.97)
HIV infection 1 (1.7) 3 (2.6) 1.000 0.60 (0.01–13.40)
Neutropenia (< 500/mm3) 2 (3.4) 7 (6.0) 0.783 0.60 (0.06–3.17)
Immunosuppressive medication 16 (27.6) 33 (28.4) 1.000 0.96 (0.41–2.14)
Onset of symptoms abroad 9 (15.5) 1 (0.9) 0.0007 16.96 (2.49–788.96) 0.042 27.01 (2.38–1,733.28)
OR: Odds ratio; CI: confidence interval; ICU: intensive care unit
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lowers the risk of selection bias. Previous antimicrobial
use may be overestimated in case–control studies that
investigate risk factors for infections if controls are se-
lected among patients with an susceptible organism [7].
Finally, the retrospective design of our study did not allow
an appropriate outcome analysis. Due to the large pro-
portion of asymptomatic urinary tract infections among
our case patients, there was no follow-up data available
for a significant number of patients. In-hospital deaths did
not differ between the two groups: three (5.2%) case pa-
tients died during hospitalization, one of which was
attributable to infection. In the control group, seven
(6.0%) deaths (two attributable to infection) were de-
tected. Antibiotic treatment in these patients appeared to
be appropriate.
There are only a few published studies in which at-
tempts were made to identify the risk factors for infections
with ESBL-producing bacteria. In their 2006 case–control
study, Tumbarello et al. [1] identified age, length of hos-
pital stay, and previous antibiotic therapy as significant
risk factors. The cases included two groups: One group
with an ESBL-positive specimen of K. pneumoniae and
one group with an ESBL-negative specimen of this
organism. The control group had no microbiological
specimen. The differences in their patient selection may
thus partly explain their results. In the 2005 study of Pen˜a
et al. [2], female gender, nasogastric tube, and prior
antibiotic use were identified as independent risk factors
for the acquisition of ESBL-producing E. coli. As in the
prior study, there were no strict matching criteria, and the
matching ratio was 1:1. In contrast to other studies [2, 8],
we did not perform molecular epidemiology and charac-
terization of ESBL types, but epidemiological findings
and antimicrobial susceptibility patterns of the isolates did
not indicate clonal or plasmid spread.
Future epidemiological studies need to focus on
mechanisms for the spread of multidrug-resistant Gram-
negative bacteria in the community as these mechanisms
are currently not understood. Although many patients
have risk factors for infections with ESBL-producing
bacteria, no risk factor can be identified in some patients.
In particular, the emergence of community-acquired
infections due to ESBL-producing bacteria, including
analysis of risk factors, appropriateness of treatment, and
outcome, need to be further evaluated. Our finding that
not only cephalosporins and quinolones but also carba-
penems and aminoglycosides were statistically significant
risk factors for ESBL infections requires confirmation in
larger studies.
In conclusion, the emergence of ESBL-producing
organisms highlights the importance of concepts for the
rational use of antibiotics as well as for infection control
measures. Our study confirms the major risk factors for
infections due to ESBL-producing bacteria, namely prior
and repeated antibiotic use, and raises concerns about the
emergence of these bacteria in the non-nosocomial and
non-health care-associated setting. The early identifica-
tion of risk factors for antibiotic resistance is crucial to
providing optimal empiric antibiotic therapy to individual
patients before the microbiology results are available. In
addition, the use of carbapenems in hospitals must be kept
to a minimum in order to lower the antibiotic selection
pressure on recently emerging carbapenemase-producing
bacteria. Because many infections due to ESBL-produc-
ing isolates occur in patients with recurrent urinary tract
infections, the rationale use of antibiotics has particularly
to be promoted in primary care where quinolones are
overused in many countries. As fosfomycin and nitrofu-
rantoin are frequently active against ESBL-producing
isolates at the present time, a change in guidelines on the
treatment of urinary tract infections may be an important
approach.
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